AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28039295
Drug: 3rd-generation CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3rd-generation CAR-T cells (1 million CAR-T cells per kg administered intravenously)
Trial: 28039295
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg intravenously every 6 hours) or IgG
Trial: 28041583
Drug: Ofatumumab plus
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab plus miniCHOP regimen (1000 mg total dose of intravenous ofatumumab, 25 mg/m2 of cyclophosphamide, doxorubicin, vincristine, and prednisone) with pre-phase treatment (oral vincristine 1 mg total dose 1 week before cycle 1 and oral prednisone 60 mg total dose for 4 days before cycle 1)
Trial: 28041583
Drug: Pre-phase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-phase treatment (oral vincristine and oral prednisone)
Trial: 28044265
Drug: Ranolazine 1000
RxNorm normalized name: ranolazine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 1000 mg twice daily for 15 weeks
Trial: 28045712
Drug: Option B+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Option B+ (lifelong antiretroviral therapy)
Trial: 28045923
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in addition to chemotherapy
Trial: 28049490
Drug: Balixafortide (POL6326)
RxNorm normalized name: Motixafortide
DrugBank: Balixafortide (DB15370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balixafortide (POL6326) at doses of 500-2500 µg/kg
Trial: 28050885
Drug: pl-VEGF165 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pl-VEGF165 gene therapy (2 intramuscular injections for a total dose of 2.4 mg)
Trial: 28050885
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy without prostaglandins and prostacyclins (Control group)
Trial: 28053173
Drug: Indicator amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indicator amino acid oxidation (IAAO) technique with l-[1-13C]Leucine
Trial: 28053674
Drug: Eccentric Training
RxNorm normalized name: SYRINGE 60ML ECCENTRIC TIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eccentric Training + Dietary Supplement (MCVC)
Trial: 28053674
Drug: Passive Stretching
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive Stretching + Dietary Supplement (MCVC)
Trial: 28053986
Drug: Preoperative chemical
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemical vestibular ablation with 1.0 mL of 40 mg/mL nonbuffered gentamicin in three intratympanic installations over 2 days, 2 months preoperatively
Trial: 28056937
Drug: Serum albumin
RxNorm normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum albumin level <3.5 g/dL
Trial: 28057644
Drug: Topical cysteamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cysteamine 0.55% eye drops
Trial: 28057654
Drug: Hypoxia exposure
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxia exposure (3-hour exposure simulating altitude of 4000 m.a.s.l.)
Trial: 28060205
Drug: Emotional self-awareness
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotional self-awareness treatment (8 lessons with psychoeducational information and skill-building exercises)
Trial: 28060358
Drug: First-generation retinal
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation retinal implant Alpha IMS
Trial: 28060358
Drug: Next-generation retinal
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Next-generation retinal implant (under assessment in a second clinical trial)
Trial: 28062705
Drug: PAK4 allosteric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAK4 allosteric modulators (PAMs) including KPT-7523, KPT-7189, KPT-8752, KPT-9307, and KPT-9274
Trial: 28063459
Drug: Angiotensin enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin enzyme converting inhibitors (86% of patients)
Trial: 28063459
Drug: Beta-blockers (84%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (84% of patients)
Trial: 28063717
Drug: Intravenous lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lipid emulsions (LE)
Trial: 28066274
Drug: 10 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 sessions standardized pain-focused EMDR in addition to treatment-as-usual (TAU)
Trial: 28068212
Drug: HZ/su vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZ/su vaccine (2 doses, 2 months apart)
Trial: 28068465
Drug: Bipolar disorder
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR MANIA AND BIPOLAR DISORDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bipolar disorder without psychotropic treatment (BD-)
Trial: 28068480
Drug: NeoCart implant
RxNorm normalized name: Neocartilage
DrugBank: Neocartilage (DB05257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeoCart implant
Trial: 28068779
Drug: Venlafaxine, up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine, up to 300 mg/day for approximately 12 weeks
Trial: 28069017
Drug: CyberKnife SBRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyberKnife SBRT at doses of 7 Gy, 7.5 Gy, 8 Gy, 8.5 Gy, 9 Gy, 9.5 Gy x 5
Trial: 28069358
Drug: Pneumococcal polysaccharide
RxNorm normalized name: pneumococcal polysaccharides (23)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal polysaccharide vaccine (PPSV) administered within 10 days after neurotrauma or neurosurgery
Trial: 28069358
Drug: Pneumococcal polysaccharide
RxNorm normalized name: pneumococcal polysaccharides (23)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal polysaccharide vaccine (PPSV) administered after ≥3 weeks post neurotrauma or neurosurgery (control group)
Trial: 28070715
Drug: Elotuzumab in
RxNorm normalized name: elotuzumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elotuzumab in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone
Trial: 28070715
Drug: Elotuzumab monotherapy
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elotuzumab monotherapy
Trial: 28070718
Drug: PF-06263507 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06263507 at 0.05 to 6.5 mg/kg
Trial: 28070720
Drug: AZD4547 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4547 (40 mg bid to 120 mg bid; 160 mg qd in Part A; 80 mg bid in Part B)
Trial: 28072473
Drug: Obinutuzumab 1000
RxNorm normalized name: obinutuzumab 1000 MG in 40 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab 1000 mg i.v. on Days 1, 8, and 15 of Cycle 1 (first infusion split over 2 days for CLL patients) and on Day 1 of Cycles 2-8 (21 days per cycle).
Trial: 28073993
Drug: Daily goal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily goal establishment of mechanical ventilation (Phase I)
Trial: 28073993
Drug: Web-based data
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based data visualization system (T3) for daily goals of mechanical ventilation (Phase II)
Trial: 28073993
Drug: Combined interventions
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined interventions (Daily goal formation and T3)
Trial: 28076247
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg intravenously/by mouth once daily for 5 days
Trial: 28076247
Drug: Ciprofloxacin 400/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 400/500 mg intravenously/by mouth twice daily for 10 days
Trial: 28076966
Drug: Everolimus once
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus once daily + sorafenib twice daily (continuous schedule)
Trial: 28077384
Drug: High-potency statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-potency statin (≥40 mg atorvastatin, ≥20 mg rosuvastatin, or 80 mg simvastatin daily)
Trial: 28077384
Drug: Low-density lipoprotein
RxNorm normalized name: Low-density lipoprotein receptor kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-density lipoprotein cholesterol <70 mg/dL at 3 months
Trial: 28078107
Drug: Bevacizumab added
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab added to induction chemotherapy and concurrent chemoradiation with cisplatin/irinotecan
Trial: 28078750
Drug: Prebiotic (2.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic (2.8 g/day HOST-G904)
Trial: 28079870
Drug: l-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine supplementation added to parenteral nutrition in 390 (39%) study subjects
Trial: 28079870
Drug: l-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine supplementation
Trial: 28081162
Drug: Interventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventional treatment (stenting and/or balloon angioplasty)
Trial: 28081820
Drug: DAPT (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT (aspirin plus thienopyridine)
Trial: 28081914
Drug: Pembrolizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (10 mg/kg intravenous every 2 weeks until disease progression or unacceptable toxic effects)
Trial: 28081953
Drug: 1 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 regimen of chemotherapy
Trial: 28081953
Drug: >1 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >1 regimen of chemotherapy
Trial: 28081953
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies in addition to chemotherapy
Trial: 28082379
Drug: Five years
RxNorm normalized name: HISTA-FIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five years of specialised early intervention (SEI) treatment (n=197)
Trial: 28082379
Drug: Two years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two years of specialised early intervention (SEI) plus three years of treatment as usual (control; n=203)
Trial: 28082419
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy for primary prevention of SCD
Trial: 28084038
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab injections monthly
Trial: 28084683
Drug: High antibiotic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High antibiotic use
Trial: 29497747
Drug: Combined Aphasia
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Aphasia and Apraxia of Speech Treatment (CAAST)
Trial: 28086010
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction of antipsychotics (olanzapine or risperidone) by up to 40%
Trial: 28086754
Drug: Nutritional status,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional status, nutritional risk; disease conditions, medication, and diet prescriptions; oral health exam, signs of swallowing difficulty and olfactory ability; observed eating behaviours, type and number of staff assisting with eating; food and foodservice satisfaction.
Trial: 28086870
Drug: Motivational Interviewing-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing-based counseling by community health agents (CHAs)
Trial: 28086942
Drug: Conventionally fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally fractionated radiotherapy (cfRT) at dose level 1 (54Gy)
Trial: 28086942
Drug: Conventionally fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally fractionated radiotherapy (cfRT) at dose level 2 (58Gy)
Trial: 28086942
Drug: Conventionally fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally fractionated radiotherapy (cfRT) at dose level 3 (62Gy)
Trial: 28086942
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with cfRT
Trial: 28086942
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with cfRT at dose level 3 (62Gy)
Trial: 28087181
Drug: 1h algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1h algorithm with hs-TnI cutoff of 6ng/L
Trial: 28087181
Drug: 99th percentile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99th percentile cutoff of 27ng/L
Trial: 28087556
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment in patients with blunt head injury
Trial: 28088395
Drug: Serum lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum lactate ≥ 2.5 mmol/L
Trial: 28088395
Drug: Lactate: pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate: pyruvate (L:P) ratio ≥ 25
Trial: 28088395
Drug: Initial lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial lactate or L:P
Trial: 28089238
Drug: Ruxolitinib 10
RxNorm normalized name: ruxolitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 10 mg orally twice a day
Trial: 28089618
Drug: Continuous (par)enteral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous (par)enteral nutrition with protein intake 1.0-3.7 g/kg/day
Trial: 28089635
Drug: Venetoclax (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (400 mg recommended phase 2 dose) plus rituximab (375 mg/m2 monthly)
Trial: 28089635
Drug: Venetoclax (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (400 mg) plus rituximab
Trial: 28089635
Drug: Venetoclax (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (50 mg)
Trial: 28089635
Drug: Venetoclax (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (20 mg)
Trial: 28089762
Drug: Concurrent weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Concurrent weekly carboplatin and paclitaxel with 74 Gy of radiation in 37 fractions (2-Gy daily fractions)
Trial: 28090295
Drug: Inhaled trepostinil
RxNorm normalized name: treprostinil Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled trepostinil
Trial: 28090299
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg/day for the first 4 weeks, then 40 mg/day for the subsequent 20 weeks
Trial: 28090335
Drug: Top-down treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top-down treatment with 5 Infliximab (IFX) infusions combined with azathioprine (AZA).
Trial: 28090335
Drug: Step-up treatment
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-up treatment with standard induction treatment (oral prednisolone or exclusive enteral nutrition) combined with azathioprine (AZA) as maintenance treatment.
Trial: 28094171
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Treatment (CRT) for 12 weeks
Trial: 28094314
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous (IV) esomeprazole for 72 hours
Trial: 28096259
Drug: Mixed meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed meal and infusion of exogenous glucose-dependent insulinotropic polypeptide (GIP)
Trial: 28097013
Drug: Polyglucosamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyglucosamine (2 tablets x 2)
Trial: 28097013
Drug: Orlistat (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (1 capsule x 3)
Trial: 28100523
Drug: Postoperative L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative L-arginine measurement
Trial: 28100523
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between logAUC(l-arginine/ADMA) and logAUC(RHI)
Trial: 28100523
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between logAUC(L-arginine/ADMA) and logAUC(BH4)
Trial: 28100530
Drug: Dexmedetomidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (2 mcg/kg bolus for 10 minutes)
Trial: 28100627
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor receptor 1
Trial: 28101105
Drug: Oral Administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Administration of nan
Trial: 28101354
Drug: gemcitabine/cisplatin/S-1 (GCS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine/cisplatin/S-1 (GCS) combination therapy intravenously at doses of 1,000 mg/m² or 25 mg/m²
Trial: 28103201
Drug: Anti-TNF alpha
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF alpha therapy (Adalimumab, Infliximab, Etanercept)
Trial: 28103201
Drug: Anti-TNF alpha
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF alpha therapy (Adalimumab, Infliximab)
Trial: 28103201
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anti-TNF alpha therapy)
Trial: 28103831
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment for nAMD
Trial: 28103831
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment for DME
Trial: 28103853
Drug: Aquatic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic Therapy
Trial: 28103853
Drug: Land-based Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Land-based Therapy
Trial: 28104208
Drug: Polymer-free drug-filled
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymer-free drug-filled stent (DFS)
Trial: 28106016
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy in low-risk patients
Trial: 28106016
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy in high-risk patients
Trial: 28106655
Drug: Transurethral polyacrylamide
RxNorm normalized name: polyacrylamide (10000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral polyacrylamide hydrogel injection
Trial: 28108386
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy and Amitriptyline (CBT+A)
Trial: 28109243
Drug: Neonatal hyperbilirubinemia
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neonatal hyperbilirubinemia treatment
Trial: 28109259
Drug: Blood-pressure lowering
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood-pressure lowering agents and statins
Trial: 28109895
Drug: Transabdominal ultrasound-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transabdominal ultrasound-guided HIFU treatment using volumetric shell ablation technique
Trial: 28109895
Drug: Transabdominal ultrasound-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transabdominal ultrasound-guided HIFU treatment
Trial: 28111925
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bevacizumab, irinotecan, and temozolomide (BIT)
Trial: 28114316
Drug: Women gaining
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women gaining below the Institute of Medicine guidelines